
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.2412 | 6.39247005134 | 35.06 | 37.42 | 34.03 | 1915413 | 35.70729466 | CS |
4 | 2.2612 | 6.45319634703 | 35.04 | 40.99 | 34.03 | 1758843 | 36.96606718 | CS |
12 | -2.0388 | -5.18251143874 | 39.34 | 46.48 | 31.005 | 2549139 | 37.28617972 | CS |
26 | 4.7912 | 14.7376191941 | 32.51 | 46.48 | 27.24 | 2559214 | 35.60890831 | CS |
52 | 19.7212 | 112.179749716 | 17.58 | 46.48 | 16.8901 | 2936508 | 29.52720357 | CS |
156 | 32.5712 | 688.608879493 | 4.73 | 46.48 | 3.96 | 3820194 | 18.09433233 | CS |
260 | 18.2112 | 95.3965426925 | 19.09 | 56.74 | 3.48 | 3063682 | 19.54670901 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions